Top Markets
Coin of the day
SQZ Biotechnologies Company SQZ Biotechnologies Company

SQZ Biotechnologies Company

SQZ
株式のランク #38920
SQZ Biotechnologies, a biotechnology firm currently in the clinical development... SQZ Biotechnologies, a biotechnology firm currently in the clinical development phase, is focused on creating cell-based therapies for various severe ailments, including cancerous growths, autoimmune disorders, and infectious diseases. Its primary experimental therapeutic, known as SQZ-PBMC-HPV, is derived from its SQZ Antigen Presenting Cells technology. This treatment is currently undergoing Phase I clinical trials, both as a standalone therapy and alongside other immune-oncology treatments, to address advanced or metastatic solid tumors positive for HPV16, encompassing cancers of the cervix, head-and-neck, anus, penis, vulva, and vagina. Furthermore, the company is progressing with SQZ-AAC-HPV, another Phase I clinical candidate targeting the same HPV16+ advanced or metastatic solid tumors, which is also being evaluated as a single agent and in conjunction with other immune-modulating agents. Beyond these, SQZ Biotechnologies is also advancing its SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers platforms. Established in 2013, the company operates from its main office in Watertown, Massachusetts.
株価
$0.05083
最終同期: 2023-09-01
時価総額
$732.57K
変化(1日)
8.15%
変化(1年)
0.00%
US
取引 SQZ Biotechnologies Company (SQZ)

カテゴリー

SQZ Biotechnologies Company(SQZ)の利益
2026 時点の利益 TTM: 0
SQZ Biotechnologies Company の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
SQZ Biotechnologies Company の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益